153 related articles for article (PubMed ID: 37390800)
1. Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naïve metastatic colorectal cancer. An AGEO prospective study.
Bachet JB; Laurent-Puig P; Meurisse A; Bouché O; Mas L; Taly V; Cohen R; Gornet JM; Artru P; Louafi S; Thirot-Bidault A; Baumgaertner I; Coriat R; Tougeron D; Lecomte T; Mary F; Aparicio T; Marthey L; Blons H; Vernerey D; Taieb J
Eur J Cancer; 2023 Aug; 189():112934. PubMed ID: 37390800
[TBL] [Abstract][Full Text] [Related]
2. Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment.
Wang F; Huang YS; Wu HX; Wang ZX; Jin Y; Yao YC; Chen YX; Zhao Q; Chen S; He MM; Luo HY; Qiu MZ; Wang DS; Wang FH; Xu M; Li YH; Xu RH
Gut; 2022 Jul; 71(7):1340-1349. PubMed ID: 34489309
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer.
Hamfjord J; Guren TK; Glimelius B; Sorbye H; Pfeiffer P; Dajani O; Lingjaerde OC; Tveit KM; Pallisgaard N; Spindler KG; Kure EH
Int J Cancer; 2021 Sep; 149(6):1385-1397. PubMed ID: 33961700
[TBL] [Abstract][Full Text] [Related]
4. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study.
Bachet JB; Bouché O; Taieb J; Dubreuil O; Garcia ML; Meurisse A; Normand C; Gornet JM; Artru P; Louafi S; Bonnetain F; Thirot-Bidault A; Baumgaertner I; Coriat R; Tougeron D; Lecomte T; Mary F; Aparicio T; Marthey L; Taly V; Blons H; Vernerey D; Laurent-Puig P
Ann Oncol; 2018 May; 29(5):1211-1219. PubMed ID: 29438522
[TBL] [Abstract][Full Text] [Related]
5. Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial.
Lueong SS; Herbst A; Liffers ST; Bielefeld N; Horn PA; Tannapfel A; Reinacher-Schick A; Hinke A; Hegewisch-Becker S; Kolligs FT; Siveke JT
Clin Chem; 2020 Dec; 66(12):1510-1520. PubMed ID: 33257977
[TBL] [Abstract][Full Text] [Related]
6. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
[TBL] [Abstract][Full Text] [Related]
7. Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer.
Elez E; Chianese C; Sanz-García E; Martinelli E; Noguerido A; Mancuso FM; Caratù G; Matito J; Grasselli J; Cardone C; Esposito Abate R; Martini G; Santos C; Macarulla T; Argilés G; Capdevila J; Garcia A; Mulet N; Maiello E; Normanno N; Jones F; Tabernero J; Ciardello F; Salazar R; Vivancos A
Mol Oncol; 2019 Sep; 13(9):1827-1835. PubMed ID: 31322322
[TBL] [Abstract][Full Text] [Related]
8. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival.
Ciardiello D; Famiglietti V; Napolitano S; Esposito L; Pietrantonio F; Avallone A; Maiello E; Cremolini C; Troiani T; Martinelli E; Ciardiello F; Martini G
Clin Colorectal Cancer; 2022 Jun; 21(2):141-148. PubMed ID: 35101346
[TBL] [Abstract][Full Text] [Related]
9. Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11).
Sunakawa Y; Satake H; Usher J; Jaimes Y; Miyamoto Y; Nakamura M; Kataoka M; Shiozawa M; Takagane A; Terazawa T; Watanabe T; Ishiguro K; Tanaka C; Takeuchi M; Fujii M; Danenberg K; Danenberg PV; Lenz HJ; Sekikawa T; Ichikawa W
ESMO Open; 2022 Jun; 7(3):100512. PubMed ID: 35688061
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer.
Tie J; Kinde I; Wang Y; Wong HL; Roebert J; Christie M; Tacey M; Wong R; Singh M; Karapetis CS; Desai J; Tran B; Strausberg RL; Diaz LA; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Ann Oncol; 2015 Aug; 26(8):1715-22. PubMed ID: 25851626
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials.
Pietrasz D; Wang-Renault S; Taieb J; Dahan L; Postel M; Durand-Labrunie J; Le Malicot K; Mulot C; Rinaldi Y; Phelip JM; Doat S; Blons H; de Reynies A; Bachet JB; Taly V; Laurent-Puig P
Br J Cancer; 2022 Feb; 126(3):440-448. PubMed ID: 34811505
[TBL] [Abstract][Full Text] [Related]
12. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
[TBL] [Abstract][Full Text] [Related]
13. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
[TBL] [Abstract][Full Text] [Related]
14. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study.
Øgaard N; Reinert T; Henriksen TV; Frydendahl A; Aagaard E; Ørntoft MW; Larsen MØ; Knudsen AR; Mortensen FV; Andersen CL
Eur J Cancer; 2022 Mar; 163():163-176. PubMed ID: 35074652
[TBL] [Abstract][Full Text] [Related]
15. Monitoring the effect of first line treatment in RAS/RAF mutated metastatic colorectal cancer by serial analysis of tumor specific DNA in plasma.
Thomsen CB; Hansen TF; Andersen RF; Lindebjerg J; Jensen LH; Jakobsen A
J Exp Clin Cancer Res; 2018 Mar; 37(1):55. PubMed ID: 29530101
[TBL] [Abstract][Full Text] [Related]
16. Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study).
Garlan F; Laurent-Puig P; Sefrioui D; Siauve N; Didelot A; Sarafan-Vasseur N; Michel P; Perkins G; Mulot C; Blons H; Taieb J; Di Fiore F; Taly V; Zaanan A
Clin Cancer Res; 2017 Sep; 23(18):5416-5425. PubMed ID: 28576867
[No Abstract] [Full Text] [Related]
17. High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study.
Huang L; Lv Y; Guan S; Yan H; Han L; Wang Z; Han Q; Dai G; Shi Y
J Transl Med; 2024 Feb; 22(1):184. PubMed ID: 38378604
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
[TBL] [Abstract][Full Text] [Related]
19. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
Jones RP; Pugh SA; Graham J; Primrose JN; Barriuso J
Eur J Cancer; 2021 Feb; 144():368-381. PubMed ID: 33422803
[TBL] [Abstract][Full Text] [Related]
20. Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment.
Kim S; Lim Y; Kang JK; Kim HP; Roh H; Kim SY; Lee D; Bang D; Jeong SY; Park KJ; Han SW; Kim TY
Br J Cancer; 2022 Sep; 127(5):898-907. PubMed ID: 35643791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
